Table 1.

Clinical/pathologic characteristics (A) and disease recurrence by tobacco status (B) among all patients with SCCOP

A. Patient demographics, tumor pathology, tobacco use, and disease recurrence for oropharyngeal cancer patients
DemographicsTotalHPV+ (n = 102)HPV− (n = 22)
Number (percent)
Gender
    Female2113 (12.8)8 (36.4)
    Male10389 (87.3)14 (63.6)
Age57.256.560.3
Race or Ethnicity
    White, non-Hispanic11698 (96)18 (81.8)
    Black, non-Hispanic52 (2.0)3 (13.6)
    Unknown32 (2.0)1 (4.6)
Primary tumor site
    Base of tongue6251 (50)11 (50)
    Tonsil5749 (48)8 (36.4)
    Oropharynx Unspecified52 (2.0)3 (13.6)
Tumor stage
    III1713 (12.7)4 (18.2)
    IVA9276 (74.5)16 (72.7)
    IVB1513 (12.8)2 (9.1)
Primary tumor (T class)
    11313 (12.8)0 (0)
    23835 (34.3)3 (13.6)
    33527 (26.5)8 (36.4)
    43827 (26.5)11 (50)
Lymph nodes (N class)
    01511 (10.8)4 (18.2)
    11611 (10.8)5 (22.7)
    2a1713 (12.7)4 (18.2)
    2b3732 (31.4)5 (22.7)
    2c2422 (21.6)2 (9.1)
    31513 (12.7)2 (9.1)
Tobacco use
    Never3333 (32.4)0 (0)
    Former early-cessation2320 (19.6)3 (13.6)
    Former late-cessation2926 (25.5)3 (13.6)
    Current3923 (22.6)16 (72.7)
Disease progression events
    LR106 (5.9)4 (18.2)
    DM1712 (11.8)5 (22.7)
    SP65 (4.9)1 (4.6)
B. Patients with recurrent disease (LR, DM, and related SP) by HPV status and tobacco history (never, former, or current)
HPV+ (n = 102)HPV− (n = 22)
Never2/33 (6.1%)0/0
    LR00
    DM10
    SP10
Former9/46 (19.6%)3/6 (50%)
    LR31
    DM51
    SP11
Current8/23 (34.8%)*8/16 (50%)
    LR34
    DM64
    SP22
Total19/102 (18.6%)11/22 (50%)

NOTE. Table 1A only includes second primaries related to original SCCOP (this excludes a prostate cancer, B-cell lymphoma, and lung adenocarcinoma; see Table 2B).

Abbreviations: BOT, base of tongue.

  • *Three HPV-positive current tobacco users suffered two events each (LR/DM; LR/DM; LR/SP), thus 11 events occurred in eight patients.